



<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.:</b> 01073/1	<b>APPLICATION NO.:</b> 10/626,941
	<b>INVENTOR:</b> Manning, et al.	
	<b>Filed:</b> 07/25/2003	<b>Group:</b> 1614

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PS	4,769,498	08/06/98	Billing et al	568	454	02/09/87
PS	5,132,453	07/21/92	Griffith et al	562	560	03/22/91
PS	5,684,008	11/04/97	Hallinan et al	514	256	11/09/94
PS	5,830,917	11/03/97	Moore et al	514	634	09/11/95
PS	5,854,251	12/29/98	Hallinan et al	514	256	11/08/95
PS	5,863,931	01/26/99	Beams et al	514	357	12/23/92
PS	5,919,787	07/06/99	Hallinan et al	514	256	10/05/98
PS	5,945,408	08/31/99	Webber et al	514	63	08/08/96
PS	5,981,511	11/09/99	Gapud et al	514	63	03/05/97
PS	6,355,689	03/12/02	Beswick et al	514	665	05/27/99
PS	6,586,747	07/01/03	Webber et al	514	562	03/23/01

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	Yes	No
PS	1 97/15555	5/1/97	W/O	C07D	233/84			X
PS	2 00/09446	24/02/00	W/O	C07D	239/42			X
PS	3 0446699	18/09/91	EP	C07K	5/06		X	
PS	4 1295880	26/03/03	EP	C07D	403/12		X	
PS	5 93/13055	08/07/93	PCT	C07K	257/14		X	
PS	6 94/12165	09/06/94	PCT	A61K	31/155		X	
PS	7 94/14780	07/07/94	PCT	C07D	239/48		X	
PS	8 95/11014	27/04/95	PCT	A61K	31/155		X	
PS	9 95/11231	27/04/95	PCT	C07D	207/22		X	
PS	10 95/24382	14/09/95	PCT	C07C	257/14		X	
PS	11 96/15120	23/05/96	PCT	C07D	257/06		X	
PS	12 96/33175	24/10/96	PCT	C07D	223/12		X	
PS	13 96/35677	14/11/96	PCT	C07C	323/58		X	
PS	14 98/30537	16/07/98	PCT	C07D	403/04		X	
PS	15 98/37079	27/08/98	PCT	C07C	257/14		X	
PS	16 99/46240	16/09/99	PCT	C07C	323/58		X	
PS	17 99/62875	09/12/99	PCT	C07D	257/06		X	
PS	18 00/26195	11/05/00	PCT	C07C	323/58		X	
PS	19 01/72703	04/10/01	PCT	C07C	323/58		X	

<b>EXAMINER</b> <i>Phyllis Spivack</i>	<b>DATE CONSIDERED</b> <i>2/21/05</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	<b>ATTY. DOCKET NO.:</b> 01073/1	<b>APPLICATION NO.:</b> 10/626,941
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>INVENTOR:</b> Manning, et al.	
(Use several sheets if necessary)	<b>Filed:</b> 08/02/02	<b>Group:</b> 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
PS	20	Moncada, S. et al; FASEB J., Vol. 9, pp. 1319-1330, 1995.
PS	21	Ohtsuka et al; J. Pharmacol. Exp. Ther., Vol. 303, Issue 1, pp. 52-57, Oct. 2002.
PS	22	Jeanguenat et al; J. Chem. Soc. Perkin. Trans. 1, pp. 2291, 1991
PS	23	Pattenden et al; Tetrahedron, Vol. 49, pp. 2131, 1993
PS	24	Seebach, D. et al; Helvetica Chimia Acta, Vol. 68, 1243, 1985.
PS	25	Sasaki, Andre N. et al; Tetrahedron Lett. Vol. 21, pp. 4263, 1980.
PS	26	O'Donnell, Martain J.; J. Org. Chem., Vol. 47, pp. 2663, 1982.
PS	27	Jenmalm, Annika et al; J. Org. Chem., Vol. 59, pp. 1139-1148, 1994.
PS	28	Chinchilla, Rafael et al; Synthesis, Vol. 4, pp. 704-717, 1999
PS	29	Bredt et al; Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 682-685, 1990
PS	30	Moore et al; J. Med. Chem., Vol. 39, 669-672, 1996
PS	31	Rodi et al; In the Biology of Nitric Oxide, Pt. 4: Enzymology, Biochemistry and Immunology; Portland Press Ltd.; London, pp. 447-450, 1995
PS	32	Misko, T. P. et al; Analytical Biochemistry, Vol. 214, pp.11-16, 1993
PS	33	Young, Robert J. et al; Bioorganic & Medicinal Chemistry Letter, Vol. 10, No. 6, pp. 597-600, 2000, "Inhibition of Inducible Nitric Oxide Synthesis Acetamidine Derivates of Hetero-Substituted Lysine and Homolysine".
PS	34	McGill, J. M. et al; Gastroenterology, Vol. 6, No. 4, Part 2, pp. A1040, April 1999, XP008029524
PS	35	Alderton, W. et al; Acta Physiologica Scandinavica, Vol. 167, No. Suppl. 645, pp. 11, Sept. 1999, XP008029544, "GW274150 is a potent, long-acting, highly selective inhibitor of iNOS (NOS-2) with therapeutic potential in post-operative ileus".
PS	36	Blasko, Eric et al; The Journal of Biological Chemistry, Vol. 277, No. 1, pp. 295-302, Issue of Jan. 04, 2002, XP002276722, "Mechanistic Studies with Potent and Selective Inducible Nitric Oxide Synthase Dimerization Inhibitors"
PS	37	McMillan, Kirk et al; PNAS; Vol. 97, No. 4, pp. 1506-1511, Feb. 15, 2000, XP002938958, "Allosteric Inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry".
PS	38	Fitch, R. et al; Nitric Oxide, Vol. 4, No. 3, pp. 201, 2000, XP001189352, "Pharmacological selectivity and therapeutic potential of inducible nitric oxide synthase (iNOS) dimerization inhibitors".
PS	39	Ichinose, Fumito et al; Nitric Oxide, Vol. 6, No. 4, pp. 403, June 2002, XP001189350, " Selective iNOS dimerization inhibitors are efficacious in acute and chronic models of Inflammation and Immunity".

<b>EXAMINER:</b> <i>Phyllis Spivack</i>	<b>DATE CONSIDERED</b> <i>2/21/05</i>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	